Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)

Inclusion Criteria: * Presence of central retinal vein occlusion (CRVO) * Age 18 years or older * ETDRS (Early Treatment Diabetic Retinopathy Study) Visual acuity between 3 and 72 letters and approximate Snellen equivalent of 20/40 to 20/800 * OCT Central foveal thickness \>250 microns * Negative pregnancy test for women of childbearing potential * Ability to provide written informed consent * Capable of complying with study protocol Exclusion Criteria: * History of glaucoma in the study eye with intraocular pressure \>21mmHg on more than one topical medication. Combination drugs are considered more than one medication * History of steroid-related glaucoma (steroid response) * Previous intraocular injection of steroid medication within 90 days * Avastin (bevacizumab) or Lucentis (ranibizumab) within 60 days * Evidence of significant retinal ischemia on fluorescein angiography in the opinion of the treating physician * Previous intraocular surgery (e.g. Cataract Surgery) with in 60 days * Concurrent ocular disease that would limit visual acuity in the opinion of the treating physician * Dense cataract that precludes clinical examination and retinal imaging of the retina * History of allergy to dexamethasone, bevacizumab, betadine * Ocular or systemic conditions that may pose a threat to the health of the subject in the opinion of the treating physician * Unwilling or unable to follow or comply with all study related procedures * Current participation in another clinical medical investigation or trial or has received any investigational drug within 12 weeks prior to enrollment